Comparison between Paras Healthcare IPO and Rubicon Research IPO.
Paras Healthcare IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Rubicon Research IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Paras Healthcare IPO is up to ₹1,800.00 Cr whereas the issue size of the Rubicon Research IPO is up to ₹1,377.50 Cr. The final issue price of Paras Healthcare IPO is and of Rubicon Research IPO is ₹485.00 per share.
| Paras Healthcare IPO | Rubicon Research IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹1 per share |
| Issue Price (Lower) | ₹461.00 per share | |
| Issue Price (Upper) | ₹485.00 per share | |
| Issue Price (Final) | ₹485.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ₹46.00 per share | |
| Market Lot Size | 30 shares | |
| Fresh Issue Size | 0 shares | 1,03,13,058 shares |
| Fresh Issue Size (Amount) | up to ₹500.00 Cr | up to ₹500.12 Cr |
| OFS Issue Size | 0 shares | 1,80,92,783 shares |
| OFS Issue Size (Amount) | up to ₹1,300.00 Cr | up to ₹877.38 Cr |
| Issue Size Total | 0 shares | 2,84,05,841 shares |
| Issue Size Total (Amount) | up to ₹1,800.00 Cr | up to ₹1,377.50 Cr |
Paras Healthcare IPO opens on , while Rubicon Research IPO opens on Oct 09, 2025. The closing date of Paras Healthcare IPO and Rubicon Research IPO is , and Oct 13, 2025, respectively.
| Paras Healthcare IPO | Rubicon Research IPO | |
|---|---|---|
| Anchor Bid Date | Oct 08, 2025 | |
| Issue Open | Oct 09, 2025 | |
| Issue Close | Oct 13, 2025 | |
| Basis Of Allotment (Tentative) | Oct 14, 2025 | |
| Initiation of Refunds (Tentative) | Oct 15, 2025 | |
| Credit of Share (Tentative) | Oct 15, 2025 | |
| Listing date (Tentative) | Oct 16, 2025 | |
| Anchor Lockin End date 1 | Nov 12, 2025 | |
| Anchor Lockin End date 2 | Jan 11, 2026 |
Paras Healthcare IPO P/E ratio is , as compared to Rubicon Research IPO P/E ratio of 55.75.
| Paras Healthcare IPO | Rubicon Research IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Paras Healthcare Ltd.'s revenue increased by 24% and profit after tax (PAT) rose by 176% between the financial year ending with March 31, 2026 and March 31, 2025.
| Company Financials (Restated Consolidated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 72.80 | 75.71 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 59.78 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 55.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹7990.21 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 12.98 | 29.02 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 10.76 | 26.45 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 3.53 | 0.73 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹4.34 | ₹8.70 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 12.98 | 29.02 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Paras Healthcare IPO Retail Individual Investors (RII) are offered 0 shares while in Rubicon Research IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Paras Healthcare IPO and 85,09,794 shares in Rubicon Research IPO.
| Paras Healthcare IPO | Rubicon Research IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 1,27,64,691 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 85,09,794 shares |
| NII | 0 shares | 42,54,896 shares |
| RII | 0 shares | 28,36,597 shares |
| Employee | 0 shares | 39,863 shares |
| Others | ||
| Total | 0 shares | 2,84,05,841 shares |
Paras Healthcare IPO subscribed in total, whereas Rubicon Research IPO subscribed 60.19x.
| Paras Healthcare IPO | Rubicon Research IPO | |
|---|---|---|
| QIB (times) | 137.04x | |
| NII (times) | 102.69x | |
| Big NII (times) | 117.75x | |
| Small NII (times) | 72.56x | |
| RII (times) | 37.39x | |
| Employee (times) | 17.77x | |
| Other (times) | ||
| Total (times) | 60.19x |
